Kilitch Drugs — 360° view

Kilitch Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹50 crore and net profit of ₹1.42 crore for the September 2026 quarter.

Kilitch Drugs (NSE: KILITCH) closed at ₹223.81 on 20 Nov 2026, up 23.4% over the past year. Its market capitalisation is ₹782 crore and it trades at 32.5 times earnings.

Share price
₹223.81 (20 Nov 2026)
Market cap
₹782 Cr (20 Nov 2026)
P/E
32.48 (20 Nov 2026)
Revenue
₹50 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
13.4% (FY26)
ROE
10.6% (FY26)
Book value
₹82.5 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹267.90 / ₹117.25 (20 Nov 2026)
1-year return
23.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: KILITCH

Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.